OBJECTIVES: To determine the effect of a porcine-derived lung surfactant, poractant alfa (Curosurf), on the respiratory outcome of very preterm @entity1 with @entity9972 ( @entity649 ), and to identify risk factors for severe @entity2107 ( @entity2107 ) in this population. DESIGN: A multicenter prospective longitudinal cohort study of 924 very preterm @entity1 with @entity649 , born between 23 and 32 weeks gestation, and treated with at least one dose of poractant alfa during the first 48 hours of life. RESULTS: The median gestational age and the mean birthweight were 29 weeks and 1210 g, respectively; babies born at <28 weeks accounted for 27.1% of the cohort. @entity1 were treated with poractant alfa 7.9 hours after birth on average. Approximatively 32% of them required at least one additional dose. The mortality rate was 23.5%. The rates of survival without @entity2107 at 28 days postnatal age and 36 weeks postmenstrual age were 38.9% and 54.0%, respectively. In the univariate analysis, factors associated with a higher risk of @entity2107 at 36 weeks postmenstrual age (severe @entity2107 ) were low gestational age, low birthweight, poor response to the first dose, and the presence of pneumothorax, @entity1986 , @entity548 , @entity2461 requiring treatment, acquired @entity358 , or @entity3166 . In the multivariate analysis, significant risk factors for severe @entity2107 were low gestational age, low birthweight, and the presence of @entity1986 , @entity358 , or @entity3166 . CONCLUSION: The rate of @entity649 -related complications in this high-risk cohort was comparable to the rates observed in the pivotal trials. In very premature @entity1 treated with poractant alfa for established @entity649 , early @entity11283 and postnatal local and/or systemic @entity32 are strongly associated with the subsequent development of severe @entity2107 .

The short-term outcome of a large cohort of very preterm @entity1 treated with poractant alfa (Curosurf) for XXXX . A postmarketing phase IV study.

@entity1 :: ('9606', 'Species') :: ['infants', 'Infants'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity3166 :: ('MESH:D020345', 'Disease') :: ['necrotizing enterocolitis'] @entity548 :: ('MESH:D006470', 'Disease') :: ['pulmonary hemorrhage'] @entity649 :: ('MESH:D012128', 'Disease') :: ['RDS'] @entity2461 :: ('MESH:D004374', 'Disease') :: ['patent ductus arteriosus'] @entity2107 :: ('MESH:D001997', 'Disease') :: ['bronchopulmonary dysplasia', 'BPD'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary infection'] @entity1986 :: ('MESH:D009395', 'Disease') :: ['interstitial emphysema'] @entity9972 :: ('MESH:D012127', 'Disease') :: ['established neonatal respiratory distress syndrome'] @entity11283 :: ('MESH:D001469', 'Disease') :: ['barotrauma']
@entity649 :: (MESH:D012128,Disease) :: ['respiratory distress syndrome']
